In the last decade the treatment of renal cell carcinoma (RCC) have changed dramatically. Currently, laparoscopic radical nephrectomy, partial nephrectomy in the presence of normal contralateral kidney as well as ablative surgery for small renal masses, are vivid options for the treatment of localized RCC. For metastatic RCC, cytoreductive nephrectomy is the standard of care prior to immunotherapy or combined treatment with tumor vaccines. On the horizon are: laparoscopic partial nephrectomy for localized disease and allogenic dendritic cell--autologous tumor cell hybrid vaccines as a non-toxic tumor vaccine. More experimental therapies involving targeting RCC cells using specific markers such as G250 are under investigation. In addition, changes in the 1997 TNM classification of RCC are anticipated. Retiring--routine adrenalectomy during radical nephrectomy and immunotherapy using tumor infiltrating lymphocytes (TIL).
|Pages (from-to)||713-717, 761|
|State||Published - Aug 2002|